Welcome to our dedicated page for PMGC Holdings news (Ticker: ELAB), a resource for investors and traders seeking the latest updates and insights on PMGC Holdings stock.
PMGC Holdings Inc. reports news across a holding-company portfolio that includes precision manufacturing, aerospace and defense supply-chain operations, industrial packaging, defense technology, and bioscience subsidiaries. Recurring company updates cover subsidiary long-term supply agreements, ITAR and aerospace quality standards, customer relationships, manufacturing capacity, and capital actions tied to acquisition-led platform development.
PMGC news also covers NorthStrive Biosciences patent filings and manufacturing work for engineered probiotic assets such as EL-22 and EL-32, as well as Pacific Sun Packaging activity in electronics and IT hardware packaging markets. Defense technology announcements describe subsidiary initiatives involving autonomous systems, counter-drone applications, and GPS-denied navigation environments.
PMGC Holdings (NASDAQ: ELAB) announced that subsidiary A&B Aerospace entered a two-year, automatically renewable Long-Term Agreement with Precision Aerospace & Defense Group (PAD Group), effective July 23, 2026, to manufacture and supply precision‑machined components for aerospace and defense programs on a purchase‑order basis, with no guaranteed minimum volume.
The framework allows PAD Group and its subsidiaries to issue orders that may support U.S. federal government prime contracts, incorporating applicable FAR and DFARS requirements. PMGC said this expands A&B Aerospace’s access to U.S. defense industrial base demand and complements its existing platform companies AGA Precision Systems and SVM Machining. Separately, PMGC Capital plans a $500,000 strategic equity investment in PAD Group’s Series F Convertible Preferred Stock, under a non‑binding term sheet subject to due diligence, definitive agreements, corporate approvals, and customary closing conditions, with no assurance of completion.
PMGC Holdings (NASDAQ: ELAB) announced that its subsidiary NorthStrive Defense Tech has signed a project services agreement with defense software and security firm Deploy360 to conduct independent validation of a patented GPS-denied autonomous drone navigation technology covered by U.S. Patent No. 12,277,716 B2.
The technology is under an exclusive aerospace and defense option to license previously secured by NorthStrive Defense Tech. Deploy360 will use its D360-Sentinel AI platform to review software, architecture, documentation and performance in simulation-based environments and deliver staged reports between August 24 and October 12, 2026, starting with project launch on August 3, 2026. The results will help NorthStrive Defense Tech decide whether to negotiate a definitive license and pursue further development or partnerships, though completion of the validation does not obligate it to exercise the option.
PMGC Holdings (Nasdaq: ELAB) announced that its subsidiary NorthStrive Defense Tech has executed a definitive Standard Exclusive License Agreement with Know-How with the Florida State University Research Foundation for U.S. Patent No. 12,291,334 and related know-how covering a multi-domain drone payload technology.
The license grants NorthStrive Defense Tech exclusive, worldwide, sublicensable patent rights in the aerospace and defense field to make, use, sell, and sublicense products, with know-how licensed on a non-exclusive basis. Financial terms include customary license and maintenance fees, earned and minimum royalties, and sublicensing revenue payments. The agreement runs for the patent life and becomes perpetual and fully paid-up after the royalty term, and is supported by a multi-year development plan targeting a working prototype, non-dilutive funding applications, first commercial sale, manufacturing capability, and cumulative net sales milestones, alongside an ongoing sponsored research program with FSURF.
PMGC Holdings (NASDAQ: ELAB) subsidiary NorthStrive Biosciences plans an independent flow cytometry (FACS) program to further characterize EL-22, an engineered Lactobacillus casei-based therapeutic candidate designed to express a latent myostatin antigen to help preserve muscle during weight loss, including with GLP-1 receptor agonists.
The study will quantify latent myostatin antigen expression on NorthStrive-manufactured L. casei and assess comparability to EL-22 material previously manufactured by MOA Life Plus. An independent contract research organization specializing in flow cytometry is expected to perform antibody-based detection, live/dead marker analysis, sample testing, and data generation across a panel of Lactobacillus samples.
According to the Company, this analytical work is intended to strengthen EL-22 product identity, manufacturing consistency, and comparability, and to help build the product characterization foundation for future IND-enabling development within NorthStrive’s engineered probiotic platform.
PMGC Holdings (Nasdaq: ELAB) merged portfolio company AGA Precision Systems into A&B Aerospace, with A&B as the surviving operating entity. The move consolidates PMGC’s aerospace precision manufacturing platform under one structure while both existing sites in Azusa and Santa Ana are expected to continue operating.
PMGC expects reduced duplicative governance and overhead, better sharing of personnel, equipment, certifications, and financial systems, and broader customer coverage and operational flexibility, while preserving existing agreements and customer relationships through AGA’s continued use as a DBA under A&B Aerospace.
NorthStrive Biosciences (NASDAQ: ELAB), a PMGC subsidiary, reported positive Phase III results from its AI-driven drug discovery program with Yuva Biosciences.
Yuva’s MitoNova™ AI platform identified four small-molecule candidates (C1–C4) that significantly increased ANT1 expression in primary human skeletal muscle cells, supporting confirmatory testing in a more mature muscle model.
PMGC Holdings (Nasdaq: ELAB), via subsidiary NorthStrive Biosciences, filed two new U.S. patent applications for EL-22 and EL-32 targeting preservation of lean muscle mass in human patients.
Claims cover use alongside GLP-1 and next-generation obesity therapies, multiple muscle-loss indications, and diverse pharmaceutical formats.
PMGC Holdings (NASDAQ: ELAB) highlighted how its U.S.-based precision manufacturing subsidiaries A&B Aerospace, SVM Machining, and AGA Precision Systems support high-growth space economy segments.
With ITAR registration and AS9100 certification, these businesses supply tight-tolerance components for satellites, launch systems, in-space manufacturing, and space infrastructure, building on existing relationships with customers such as SpaceX, Moog, and LBNL. Space-related programs represented about 5.7% of operating-company revenue over the past two years, which PMGC views as a foundation for future space-sector growth.
PMGC Holdings (Nasdaq: ELAB) subsidiary NorthStrive Defense Tech executed a binding term sheet for an exclusive, worldwide, sublicensable license to U.S. Patent No. 12,291,334 covering multi-domain drone payload transport across air and water for aerospace and defense.
The deal includes life-of-patent rights and a 12‑month sponsored research program to deliver a small‑payload prototype, test data, and an option on new inventions.
PMGC Holdings (NASDAQ: ELAB) signed a non-binding LOI to acquire a 76% cash stake in an Arizona-based precision machining and contract manufacturing company, with existing owners retaining 24%.
The Target generated about $5.46M revenue and $1.05M EBITDA in FY 2025, has >20% adjusted EBITDA margin and >30% aerospace/defense revenue, AS9100 and ISO 9001:2015 certifications, ITAR registration, recurring revenue, and multi-year backlog.
The proposed deal supports PMGC’s U.S. manufacturing roll-up strategy and would expand aerospace, defense, semiconductor, and industrial exposure if closed, but remains subject to audit, definitive agreements, approvals, and other customary conditions.